Shockwave血管内碎石术治疗钙化髂动脉闭塞性疾病的IVLIAC注册研究中远期结局
IVLIAC多中心注册研究纳入2021年2月至2024年5月四中心连续接受血管内碎石术(IVL)治疗的钙化髂动脉患者,评估其安全性和有效性并探索是否置入支架的新算法。共治疗86例患者100条髂动脉,中位随访20个月,技术成功率99%,24个月一期通畅率95%、辅助一期通畅率98%、二期通畅率100%,仅1例髂动脉破裂,无远端栓塞。作者结论认为IVL是钙化髂动脉闭塞性疾病安全有效的治疗选择,中远期通畅率良好且支架置入率低,但需进一步研究证实。
要点
- 86例患者100条钙化髂动脉接受IVL,中位随访20个月,技术成功率99%。
- 24个月一期通畅率95%(95%CI 85.1%-98.1%),辅助一期通畅率98%(95%CI 92%-99.5%),二期通畅率100%。
- IVL单独治疗组与IVL加支架组的一期通畅率无统计学显著差异(P=24)。
核心结论
- 作者认为IVL是钙化髂动脉闭塞性疾病安全有效的治疗选择。
- 这项多中心经验显示,尽管支架置入率极低,一期通畅率的中远期结果令人期待,并保留了未来的治疗选择。
- 需要进一步研究来证实这些发现。
研究设计与样本
- 多中心注册研究,纳入2021年2月至2024年5月四中心连续接受Shockwave血管内碎石术(IVL)治疗钙化髂动脉的患者。
- 共治疗86例患者(52例男性;平均年龄74±9岁)的100条髂动脉。
- IVL指征为Rutherford分级≥3级的髂动脉病变伴中重度钙化,并基于新算法:狭窄病变采用IVL单独治疗±必要时临时支架置入,慢性完全闭塞病变采用IVL作为计划支架置入的血管准备。
- 主要终点为一期通畅率,同时分析辅助一期通畅率、二期通畅率和免于髂动脉并发症。
- 比较IVL单独治疗组(IVL ONLY)与IVL加辅助支架组(IVL + STENT)的临床和手术数据;IVL ONLY的指征基于辅助完成评估(血管外超声和跨病变压力梯度)。
主要发现
- 中位随访20个月(范围1-45个月),55%的患者存在严重肢体缺血,其中75%有重度钙化(180°-360°)。
- 平均靶病变长度40.95±29.25 mm,平均狭窄84%±10%(12例慢性完全闭塞)。
- 技术成功率为99%;77%的靶病变采用IVL ONLY治疗,其余23%采用IVL + STENT(临时支架11%,计划支架12%)。
- 最终血管造影平均残余狭窄为14.95%±14%;所有IVL ONLY病例均检测到血管外超声成像改善(双相替代单相/钝化的同侧股总动脉波形)和/或跨病变压力梯度降低(平均-71%)。
- 24个月一期通畅率和辅助一期通畅率分别为95%(95%CI 85.1%-98.1%)和98%(95%CI 92%-99.5%),二期通畅率为100%;IVL ONLY组与IVL + STENT组的一期通畅率无统计学显著差异(P=24)。
关键数值与推荐
- IVL指征:Rutherford分级≥3级的髂动脉病变伴中重度钙化。
- 新算法:狭窄病变采用IVL单独治疗±必要时临时支架置入;慢性完全闭塞病变采用IVL作为计划支架置入的血管准备。
- IVL ONLY指征基于辅助完成评估:血管外超声和跨病变压力梯度。
- 24个月一期通畅率95%(95%CI 85.1%-98.1%),辅助一期通畅率98%(95%CI 92%-99.5%),二期通畅率100%。
- IVL ONLY组与IVL + STENT组的一期通畅率比较P=24;较长靶病变与靶病变血运重建相关P=24。
临床怎么用
- 原文未据此给出推荐。
- 作者结论认为IVL是钙化髂动脉闭塞性疾病安全有效的治疗选择,并显示中远期一期通畅率结果令人期待且支架置入率极低。
- 作者指出需要进一步研究来证实这些发现。
局限性
- 需要进一步研究来证实这些发现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The aim of this study was to evaluate safety and efficacy of intravascular lithotripsy (IVL) treatment in calcified iliac arteries and explore a new approach to determining whether to stent or not to stent calcific iliac vessels. METHODS: All consecutive patients who underwent IVL (Shockwave Medical) for calcified iliac arteries from February 2021 to May 2024 at four centers were included. Indication for IVL was Rutherford category ≥3 in iliac lesions with moderate-to-severe calcification and was based on a new algorithm: IVL as stand-alone therapy ± provisional stenting in case of stenosis, or IVL as vessel preparation for planned stenting in cases of chronic total occlusion. The primary endpoint was primary patency; assisted primary patency, secondary patency, and freedom from iliac complications were also analyzed. Clinical and procedural data were compared between two groups: IVL stand-alone therapy (IVL ONLY) vs IVL with adjunctive stenting (IVL + STENT). Indication for IVL ONLY was based on adjunctive completion assessments (extravascular ultrasound and translesional gradient pressure). A Cox regression univariate analysis between cases with or without target lesion revascularization was performed. RESULTS: In total, 100 iliac arteries were treated in 86 patients (52 male; mean age, 74 ± 9 years). Median follow-up was 20 months (range, 1-45 months). Critical limb ischemia was present in 55% of the patients, the majority of whom (75%) had severe calcifications (180°-360°). The mean target lesion length was 40.95 ± 29.25 mm with a mean stenosis of 84% ± 10% (12 chronic total occlusions). Technical success was 99%. The target lesions were treated with IVL ONLY in 77% of cases, whereas IVL + STENT was employed in the remaining 23% of the cases (provisional stenting, 11%; planned stenting, 12%). Mean residual stenosis was 14.95% ± 14% at final angiogram. Extravascular ultrasound with improved imaging (bi-triphasic in place of monophasic/blunted ipsilateral common femoral artery waveform), and/or decreased translesional gradient pressure (mean, -71%) were detected in all IVL ONLY cases. Primary patency and assisted primary patency at 24 months were 95% (95% confidence interval, 85.1%-98.1%) and 98% (95% confidence interval, 92%-99.5%), respectively, whereas secondary patency was 100%. Primary patency showed no statistically significant difference (P = 24) between the IVL ONLY and IVL + STENT groups. There was one iliac rupture and no distal embolization. Longer target lesions (P = 24) were significantly related to target lesion revascularization. CONCLUSIONS: IVL is a safe and effective treatment option for calcific iliac occlusive disease. This multicenter experience shows promising mid-term results in terms of primary patency despite the very low stenting rate, preserving future treatment options. Further studies are needed to confirm these findings.
引用
- Fazzini S, Turriziani V, Lomazzi C, et al. Mid-term outcomes of Shockwave intravascular lithotripsy in the IVLIAC Registry for the treatment of calcified iliac occlusive disease. J Vasc Surg. 2025. PMID: 40268258. doi:10.1016/j.jvs.2025.04.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。